Cantor Fitzgerald Reiterates Overweight Rating on Global Blood Therapeutics (GBT) Following Analyst Day

October 8, 2019 11:48 AM EDT Send to a Friend
Cantor Fitzgerald analyst Elemer Piros reiterated an Overweight rating and $110.00 price target on Global Blood Therapeutics (NASDAQ: GBT) after ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login